tradmap

CDNA Caredx, Inc.

$85.89 -1.68%

Data as of close

Healthcare · Services-Medical Laboratories

Caredx, Inc. (CDNA) is a healthcare company in the Services-Medical Laboratories industry, with a market capitalization of $4.5 billion. Shares last traded at $85.89, 5.1% below their 52-week high. Over the past year the stock is up 493.4%. CDNA trades at a price-to-earnings ratio of 35.08, in line with the Services-Medical Laboratories median of 34.77. Net profit margin is 25.9%, above the peer median of -5.4%. Revenue grew 13.8% year over year.

Market Cap
$4.5B
Shares Out
52.5M
EPS (TTM)
$2.39
P/E (TTM)*
35.08
P/S Ratio
9.07
P/B Ratio
9.65
Dividend / Share
—
Dividend Yield
—
52-Week High
$90.46
52-Week Low
$14.28
Volume (venue)
287,278
Avg Vol (3m, venue)
81,546.508

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
+24.33%
1M
+27.88%
3M
+82.36%
6M
+310.17%
YTD
+355.77%
1Y
+493.37%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
78.78
SMA (50)
$60.92
SMA (200)
$34.02
Price vs SMA50
+40.98%
Price vs SMA200
+152.43%
ATR (14)
$5.03

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$497M
Net Income
$129M
Gross Margin
16.4%
Operating Margin
23.4%
Net Margin
25.9%
Return on Equity
27.5%
Return on Assets
20.1%
Current Ratio
2.31
Debt / Equity
0.00
Revenue Growth (YoY)
+13.8%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-09-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q3 2026 $0.35 2026-10-29
Q2 2026 $2.07 2026-07-30
Q1 2026 $0.05 2026-04-28
Q4 2025 (derived) -$0.08 2026-02-25
FY 2025 -$0.40 2026-02-25
Q3 2025 $0.03 2025-11-04

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Services-Medical Laboratories peers

CDNA vs 14 industry peers (Services-Medical Laboratories), by market cap. Data as of close

P/E vs peers
35.08 / 34.77 med
+1% premium
P/S vs peers
9.07 / 5.00 med
+81% premium
Net margin vs peers
25.9% / -5.4% med
above median
1–14 of 14
NTRANatera, Inc.$54.6B—20.18-7.1%-8.49%
LHLabcorp$28.9B28.771.986.9%-1.65%
DGXQuest Diagnostics$27.6B24.442.339.5%-0.44%
GHGuardant Health, Inc.$22.9B—19.38-38.3%-4.45%
CAICaris Life Sciences, Inc.$9.1B86.269.1610.6%-6.50%
GRALGrail, Inc.$6.0B———-6.79%
RDNTRadnet, Inc.$5.8B—2.54-0.9%-0.54%
BLLNBilliontoone, Inc.$5.2B138.0913.109.5%-2.52%
CDNACaredx, Inc.$4.5B35.089.0725.9%-1.68%
VCYTVeracyte, Inc.$3.9B34.457.0220.4%-1.87%
CELCCelcuity Inc.$3.3B———-2.90%
FTREFortrea Holdings Inc.$1.9B—0.72-2.6%-5.99%
PSNLPersonalis, Inc.$1.7B———-0.44%
LMRILumexa Imaging Holdings, Inc.$1.1B———-2.32%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.